维多利祖马布剂量升级解决了两个患者的免疫检查点抑制剂诱导的结肠炎
Cong Wang1, Nikhil Nayee2, Jacqueline M Garrick2
1College of Medicine, University of Arizona, Phoenix, Arizona, USA.
在两名患者中,翻一番vedolizumab剂量有效治疗了耐火性免疫检查点抑制性结肠炎 (CIC). 这种方法解决了症状而没有复发,表明剂量升级是管理这种ICI副作用的可行策略.
科学领域:
- 胃肠病学 胃肠病学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 免疫检查点抑制剂 (ICI) 可以引起大肠炎,这是一个显著的副作用.
- 维多利祖马布是一种α4β7抗体,治疗IBD,并用于ICI大肠炎 (CIC) 的非标签治疗.
- 维多利祖马布的剂量升级在IBD中已经显示出有效性,但在CIC中还没有.
研究的目的:
- 评估在耐火性CIC患者中升级vedolizumab剂量的疗效.
- 报告用于CIC管理的双剂量vedolizumab的临床经验.
主要方法:
- 两名患有CIC耐标准治疗的患者的病例系列.
- 最初的治疗包括infliximab,类固醇和标准的300毫克vedolizumab.
- 升级治疗涉及600毫克的双倍剂量vedolizumab.
主要成果:
- 这两位患者对标准的vedolizumab剂量表现出不完全的反应.
- 在这两种情况下,600毫克的双倍剂量vedolizumab解决了结肠炎症状.
- 在剂量升级后,不需要复发或进一步治疗.
结论:
- 对耐火性CIC而言,将vedolizumab剂量升级至600mg可能是有效的.
- 这种方法为那些对标准CIC疗法没有反应的患者提供了潜在的治疗策略.
- 需要进行进一步的研究,以调查CIC患者的vedolizumab剂量升级.
更多相关视频
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
09:08Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
